| |
| | Journal of Family Practice: Calcitonin in the treatment of osteoporotic bone pain |
 | | Calcitonin may have an advantage over other analgesics in the treatment of bone pain resulting from an osteoporotic compression fracture, because, in addition to the observed analgesic effect, it is useful in treating the underlying disorder. |
 | | Calcitonin, a natural hormone produced by the parafollicular "C" cells of the thyroid, has been investigated for its potential role in halting or reversing the progression of osteoporosis.[1-5] In humans, calcitonin is believed to inhibit osteoclastic bone resorption and to exert an analgesic effect on diseases associated with bone pain.[6-16] |
 | | Calcitonin was first discovered in 1962, but its exact physiologic role is still uncertain.[17] Its principal actions are inhibiting osteoclastic bone resorption, and, in higher doses, lowering serum calcium.[17] Calcitonin has been approved for treatment of osteoporosis, hypercalcemia, and Paget's disease because of this positive effect on bone mass. |
| www.findarticles.com /p/articles/mi_m0689/is_n1_v35/ai_12436052 (1160 words) |
|